New drugs for the treatment of hepatocellular carcinoma

Liver International

Volumn 29, Issue SUPPL. 1, 2009, Pages 148-158

  Boucher, Eveline ^a   Forner, Alejandro ^a   Reig, Maria ^a   Bruix, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Advanced; Hepatocellular carcinoma; Molecular pathways; Molecular targeted therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; THALIDOMIDE; VASCULAR TARGETING AGENT; WNT PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLEEDING; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER FUNCTION; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; RISK FACTOR; SOMNOLENCE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DRUG DELIVERY SYSTEMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 59149093765     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01929.x     Document Type: Conference Paper

References (62)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002, 2005; 55: 74-108.
2. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10.
3. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: A case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-7.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127(Suppl. 1): S5-16.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
6. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104.
7. Sherman M. Alphafetoprotein: An obituary. J Hepatol 2001; 34: 603-5.
8. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-76.
9. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52.
10. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779-88.
11. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
12. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
13. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76.
14. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674-87.
15. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-27.
16. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
17. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
18. Hayashi J, Aoki H, Kajino K, et al. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology 2000; 32: 958-61.
19. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-63.
20. O'Dwyer P, Giantonio B, Levy D, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006; 24(Suppl.): 213S.
21. Ramanathan RK, Belani CP, Singh DA, et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol, 2006 ASCO Annu Meet Proc Part I 2006; 24(18S (June 20 Supplement)): 4010.
22. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: Results of a multicenter phase 2 study. Cancer 2008; 112: 2733-9.
23. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581-9.
24. Thomas M, Chadha R, Iwasaki M, Glover K, Abbruzzese J. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25(Suppl.): 4567S.
25. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
26. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
27. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.
28. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-72.
29. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
30. Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of Sorafenib vs placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008; 26 (Suppl 15): 4509.
31. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
32. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
33. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
34. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
35. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
36. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
37. Abou-Alfa G, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008; 26(Suppl. 15): 4518.
38. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials. Cancer Chemother Pharmacol 2008; 61: 535-48.
39. Abou-Alfa G, Johnson P, et al. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma [abstract]. In: Proceedings of the 14th European Cancer Conference of the European Cancer Organisation (ECCO), 23-27 September 2007, Barcelona, Spain, abstract 3500.
40. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007; 6: 138-46.
41. Teo M, Huynh HT, Hee SW, et al. FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in hepatocellular carcinoma. J Clin Oncol, 2007 ASCO Annu Meet Proc Part I 2007; 25(18S (June 20 Supplement)): 4538.
42. Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-5.
43. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
44. Huynh H, Chow KP, Soo KC, et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2008. DOI:
45. Campos LT, Stephenson J, Swan F, et al. Daily dose of perifosine less toxic than weekly and active in patients with hepatocellular carcinoma (HCC). J Clin Oncol, 2007 ASCO Annu Meet Proc Part I 2007; 25 (18S (June 20 Supplement)): 15072.
46. Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 544-9.
47. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
48. Barbany G, Hoglund M, Simonsson B. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med 2002; 347: 539-40.
49. Lin AY, Fisher GA, So S, Tang C, Levitt L. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol 2008; 31: 84-8.
50. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-8.
51. Kanai F, Yoshida H, Tateishi R, et al. Final result of a phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma. J Clin Oncol 2008; 26(Suppl. 15): 4589.
52. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial. Cancer 2005; 103: 749-55.
53. Faivre S, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25(Suppl.): 3546S.
54. Zhu A, Sahani D, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007; 25(Suppl.): 213S.
55. Citterio G, Santoro A, Scalamogna R, et al. A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2008; 26(Suppl.) (abstract 15544).
56. Venook AP, Poon R, Kang YK, et al. Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol, 2007 ASCO Annu Meet Proc Part I 2007; 25 (18S (June 20 Suppl.ement)): 15055.
57. Berlin JD, Powell ME, Su Y, et al. Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates. J Clin Oncol 2008; 26(Suppl. 15): 4592.
58. Craxi A, Porta C, Sangiovanni S, et al. Baseline transaminase levels and efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): A subgroup analysis of SHARP. 2008 Gastrointestinal Cancers Symposium, abstract 197.
59. Sherman M, Mazzaferro V, Amadori D, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial. J Clin Oncol 2008; 26(Suppl. 15): 4584.
60. Raoul J, Santoro A, Beaugrand M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial. J Clin Oncol 2008; 26(Suppl. 15): 4587.
61. Greten T, Scherübl J, Scheulen M, et al. Baseline transaminase levels and efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): A subgroup analysis of SHARP. 2008 Gastrointestinal Cancers Symposium, abstract 197.
62. Bolondi L, Caspary W, Bennouna J, et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): Subgroup analysis of the SHARP trial. 2008 Gastrointestinal Cancers Symposium. abstract 129.